FDAnews
www.fdanews.com/articles/72396-transgene-presents-positive-data-of-mva-muc1-il2-in-prostate-cancer

Transgene Presents Positive Data of MVA-MUC1-IL2 in Prostate Cancer

May 17, 2005

Transgene has reported results of a Phase II clinical study with Transgene's therapeutic cancer vaccine MVA-MUC1-IL2 in prostate cancer.

In this study, 40 men with rising Prostate Specific Antigen (PSA), who have had primary local treatment by surgery or radiation, were treated with MVA-MUC1-IL2 alone. In this clinical situation, also known as biochemical failure, a rising PSA is the sole manifestation of a silently progressing disease. PSA may, therefore, be used as a surrogate marker of the disease evolution.

In 63 percent of the patients, MVA-MUC1-IL2 induced a significant increase in the time the PSA takes to double. In 30 percent of the patients, the PSA doubling time (PSA-DT) was more than twice as long, in comparison with the prevaccination status. These findings indicate that MVA-MUC1-IL2 is biologically active against prostate cancer. It is expected that this effect on the PSA-DT will translate into a slowing of the disease progression.